Pfizer Abandons Ionis’ Cardiovascular and High Triglyceride Program
Summary : Pfizer and Ionis Pharmaceuticals announced that the former is abandoning its vupanorsen program for cardiovascular (CV) risk reduction and severe…
Summary : Pfizer and Ionis Pharmaceuticals announced that the former is abandoning its vupanorsen program for cardiovascular (CV) risk reduction and severe…
Abstract: The European Commission has approved Pfizer`s first-of-its-kind oral Janus kinase (JAK) inhibitor XELJANZ® (Tofacitinib) 5 mg twice daily for the treatment…
SYNOPSIS US government contracts for approximately $1 billion (USD) are now in place to purchase Sotrovimab, further expanding access nationwide Sotrovimab, an…
SYNOPSIS: VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s…
KEYPOINTS: AbbVie announces that the European Commission (EC) has approved SKYRIZI (Risankizumab, 150 mg, subcutaneous injection at week 0, week 4, and…
KEYPOINTS: Novavax Inc and partner Serum Institute of India said on Monday they received emergency use authorization for their Covid-19 vaccine in…